Skip to main content
. 2022 Oct 13;107(4 Suppl):84–89. doi: 10.4269/ajtmh.21-1330

Table 1.

Selected NMCP operational and implementation research priorities addressed in collaboration with the WA-ICEMR

Malaria Control Program component* Operational challenges encountered in implementing malaria control program component Operational research performed to mitigate operational challenges
Malaria case management and treatment
  • Lack of adequate and current management and treatment practices at local health facilities

  • Performance improvement techniques offered to health workers on a regular basis to improve adherence to current clinical treatment guidelines as well as training in malaria diagnosis

Malaria in pregnancy
  • Low health worker compliance with guidelines for administration of IPTp in health facilities

  • Low coverage and uptake of IPTp with three doses of SP

  • New service delivery strategies and behavior change interventions to increase SP compliance

SMC
  • Limited knowledge on level of compliance, side effects and possible barriers to SMC treatment

  • Post-SMC surveys on compliance and possible SMC-caused side effects and drug metabolite measurement (ELISA) for compliance

  • Lack of knowledge on the long-term impact of SMC on malaria epidemiology and transmission (rebound effect on immune response, burden of the disease, parasite genotypes and possible drug resistance development)

  • SMC impact studies on prevalence and incidence of Plasmodium falciparum infection and disease

  • Cohort-based immunogenomics studies to measure the possible impact of SMC on immunological indices

  • Molecular/genomic surveillance of antimalarial drug resistance markers studies and potential impact on malaria incidence

  • Need for evaluation of alternative drugs for SMC

  • Test of DHA-PQ as an alternative drug for SMC

Antimalarial drug resistance
  • Lack of knowledge on current prevalence and the possible impact of molecular antimalarial drug resistance markers relevant for treatment (ACTs) and preventive treatment

  • Repeated molecular surveillance of antimalarial drug resistance markers and ex vivo testing

Malaria mosquito transmission
  • Need for updated knowledge on the impact of current vector control strategies on vector abundance, species composition, and biting behavior

  • Longitudinal monitoring of entomological parameters at WA-ICEMR study sites

  • Lack of knowledge on vector habitat and survival strategies through the dry season

  • Studies of vector ecology and larval source identification applying drones, ground-truthing and GIS/RS

LLIN use
  • Lack of updated knowledge on coverage, usage, and residual effects of ITNs on adult mosquitoes

  • Coverage and usage patterns of ITNs regarding trends in malaria transmission

  • Need for evidence on the effectiveness of the deployment of next-generation ITNs

  • Assessment of the residual effect of insecticides

  • Testing for the effectiveness of next-generation ITNs

Insecticide resistance
  • Need for regular, routine information on insecticide resistance profiles of primary malaria vectors

  • Continuous monitoring of susceptibility patterns in vector populations, particularly in intervention areas (molecular resistance markers, genomic surveillance)

Monitoring and evaluation
  • Large amounts of data at both the individual and molecular levels, with limited capacity for data modeling and analysis

  • Assistance with analyses for routine data monitoring

  • Application of monitoring data to improve program implementation

  • Data sharing and continuous analyses of research data to assist NMCP

ACT = artemisinin-based combination therapy; DHA-PQ = dihydroartemisinin-piperaquine; ELISA = enzyme-linked immunosorbent assay; GIS = geographic information systems; ITN = insecticide-treated net; IPTp = intermittent preventive treatment of malaria during pregnancy; LLIN = long-lasting insecticide-treated bed net; NMCP = Mali National Malaria Control Program; RS = remote sensing; SMC = seasonal malaria chemoprevention; SP = sulfadoxine-pyrimethamine; WA-ICEMR = West Africa International Center of Excellence in Malaria Research.

*

Performed by the Mali NMPC.